Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

The <keyword id="54656" type="General" weightage="20" keywordseo="indian-embassy" source="Orion">Indian Embassy</keyword> in Rome said on Friday that the country has recognised the <keyword id="9617748" type="General" weightage="100" keywordseo="covishield" source="Orion">Covishield</keyword> vaccine and people who have received the jab are now eligible for a <keyword id="9276440" type="General" weightage="80" keywordseo="green-pass" source="Orion">Green Pass</keyword>. With <keyword id="21474" type="General" weightage="80" keywordseo="italy" source="Orion">Italy</keyword>'s recognition, a total 19 European Union (EU) nations have given their go-ahead to Covishield. This is the outcome of a G20 Health Ministers meeting between Union Health Minister <keyword id="2607815" type="General" weightage="20" keywordseo="mansukh-mandaviya" source="Orion">Mansukh Mandaviya</keyword> and his Italian counterpart Roberto Speranza, the Embassy said in a tweet. "Indian vaccine CardHolders are now eligible for the Green Pass," it added Prior to this, Italy had recognised Comirnaty - Pfizer, Moderna, Vaxzervria - AstraZeneca, and <keyword id="92247" type="General" weightage="20" keywordseo="johnson-johnson" source="Orion">Johnson &amp; Johnson</keyword> vaccines as valid. The other 18 EU nations that have recognised the Covishield vaccine are Austria, Belgium, Bulgaria, Croatia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Latvia, Netherlands, Romania, Slovenia, Spain, Sweden, and Switzerland. Meanwhile, the vaccine row with the UK continues as it has recognised the jab but a 10-day quarantine has been made mandatory which will come into the effect from October 4. Terming the present UK travel restrictions as discrimatory, Union Health Secretary Rajesh Bhushan said that "we have the right to reciprocate in the same manner". However, the British High Commissioner to India Alex Ellis said that Covishield vaccine is not a problem and the UK is open to travel. "We're clear Covishield is not a problem. The UK is open to travel and we're already seeing a lot of people going from India to the UK, be it tourists, business people or students". SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/environment/news/heres-how-researchers-are-considering-fly-ash-recycled-phones-and-slag-to-lower-global-carbon-emissions-from-cement/articleshow/86477965.cms">Here’s how researchers are considering fly ash, recycled phones and slag to lower global carbon emissions from cement</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/bharat-bandh-called-by-dmk-on-september-27-to-protect-the-rights-of-the-farming-community/articleshow/86474697.cms">Bharat Bandh called by DMK on September 27 to 'protect the rights of the farming community'</a>

After UK and US, Italy also gives green pass to Covishield vaccine

<keyword id="18568" type="COMPANY" weightage="20" keywordseo="kathmandu">Kathmandu</keyword>, Ahead of signing a major Covid <keyword id="24209" type="PERSON" weightage="20" keywordseo="vaccine">vaccine</keyword> deal with <keyword id="3658" type="LOCATION" weightage="20" keywordseo="India">India</keyword>, probably on Friday, Nepal's Department of Drug Administration (DDA) has given permission for the <keyword id="9156702" type="UNKNOWN" weightage="20" keywordseo="emergency-use">emergency use</keyword> of India-made coronavirus vaccine Covishield in the country. Nepal's Foreign Minister Pradeep Gyawali is currently in New Delhi to take part in the sixth meeting of Nepal-India Joint Commission. One of the major agreements that both sides are likely to ink is on cooperation in Covid vaccine manufactured in India. The vaccine, developed by the <keyword id="30725" type="COMPANY" weightage="20" keywordseo="Oxford-university">Oxford University</keyword> and Astra-Zeneca and produced by the <keyword id="95879" type="COMPANY" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword>, has been given conditional permission for emergency use, the department said. The DDA had two days ago called for the registration of vaccines to be used for emergency use. This is the first time that any Covid-19 vaccine has been approved for use in Nepal. Other manufacturing countries like China and Russia were also interested in providing vaccines to Nepal but due to climatic conditions, pricing, logistic facility and ease of import, Nepal preferred the Indian Covid vaccine. India has already permitted the use of Covishield as well as Covaxin of <keyword id="149108" type="PERSON" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword>. SEE ALSO: <a href="https://www.businessinsider.in/defense/news/these-amazing-facts-about-the-indian-army-will-make-you-beam-with-pride/slidelist/80270052.cms">Army Day 2021: These amazing facts about the Indian Army will make you beam with pride</a> <a href="https://www.businessinsider.in/business/corporates/news/hcl-tech-clocks-in-nearly-27-jump-in-profit-crosses-the-10-billion-revenue-in-third-quarter-of-year-2020-21/articleshow/80278852.cms">HCL Tech clocks in nearly 27% jump in profit, crosses the $10 billion revenue milestone with one more quarter left</a> <a href="https://www.businessinsider.in/india/news/india-will-begin-its-covid-19-vaccination-drive-tomorrow-heres-everything-you-need-to-know/articleshow/80281740.cms">India will begin its COVID-19 vaccination drive tomorrow — here’s a look at how the world’s largest vaccine rollout is set to take place</a>

Nepal approves Covishield vaccine for emergency use

<keyword id="9626040" type="UNKNOWN" weightage="20" keywordseo="Covishield-vaccine">Covishield vaccine</keyword> offers protection from double mutant variant of novel coronavirus, shows a study by the <keyword id="395778" type="COMPANY" weightage="20" keywordseo="Centre-for-Cellular-and-Molecular-Biology">Centre for Cellular and Molecular Biology</keyword> (CCMB). CCMB Director Rakesh K. Mishra termed this as a very preliminary but encouraging result. "Early results using in vitro neutralisation assay show that both convalescent (prior infection) sera and <keyword id="9617748" type="COMPANY" weightage="20" keywordseo="covishield">Covishield</keyword> vaccinated sera offer protection against the B.1.617 variant, aka double mutant," he said in a tweet. The CCMB's finding came close on the heels of an announcement by the Indian Council of Medical Research (ICMR) that Covaxin neutralises multiple variants of SARS-CoV-2 and effectively works against the double mutant strain as well. Covaxin is India's first indigenous Covid vaccine developed by Bharat Biotech in collaboration with ICMR. Covishield has been developed by Oxford-Astrazeneca and is being produced by <keyword id="95879" type="COMPANY" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword>, <keyword id="2094" type="COMPANY" weightage="20" keywordseo="Pune">Pune</keyword>. Both Covaxin and Covishield are part of India's ongoing Covid vaccination programme. The 'double mutant' (B.1.617) is said to be responsible for the current surge in Covid-19 cases in <keyword id="13126" type="COMPANY" weightage="20" keywordseo="Maharashtra">Maharashtra</keyword> and other states in India. Scientists earlier feared that vaccines may not offer protection from 'double mutant' as it may escape the immune system. After the CCMB's latest announcement that Covishield too offers protection from 'double mutant', experts say this again underscore the need for people to get vaccinated. CCMB scientist Divya Tej Sowpati tweeted that the convalescent sera is from September 2020, hence most likely of an infection of a variant which is not B.1.617. He also pointed to misinformation and confusion about the circulating SARS-CoV-2 variants in India. Though B.1.617 is called 'double mutant', it is characterised by more than 15 mutations. "It got dubbed the 'double mutant' because of two <keyword id="16898" type="COMPANY" weightage="20" keywordseo="Spike">spike</keyword> mutations, L452R and E484Q, which were mutations of concern because of their immune escape properties, and possible high infectivity," wrote Sowpati, who is leading Covid-19 genomics at CCMB. According to him, B.1.618 is not the 'triple mutant'. "Triple Mutant: Again, WRONG name, because it has many more defining mutations. Dubbed 'triple' because in addition to the two mutations, it also has V382L in its Spike. This is a sub-lineage of B.1.617, found mainly in MH samples and also a bit in other states." He also clarified that B.1.618 which was first sampled in West Bengal in late October 2020, has nothing to do with B.1.617, except for a couple of shared variants that all SARS-CoV-2 strains have at this point such as D614G. According to him, the main concern with B.1.618 is that it is found in growing proportions in West Bengal and has the spike del145-146 as well as E484K, both of which are known immune escape mutations. The scientist said that the names of "double" and "triple" mutants are wrong and misleading and that they have no connection to the lineage seen in West Bengal. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/environment/news/worsening-air-quality-amid-the-surging-covid-19-cases-could-add-to-the-pressure-on-indias-healthcare-system/articleshow/82213498.cms">Air pollution is back with a vengeance as industries play catch up — and that could further worsen the COVID-19 pandemic</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/checkout-in-images-how-oxygen-is-being-transported-across-the-country-by-air-rail-and-road/slidelist/82212220.cms">By air, rail and road – how oxygen is being transported across India amidst a severe COVID-19 crisis</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/aiims-icmr-new-guidelines-for-treatment-of-covid-19-patients-with-moderate-case/articleshow/82211333.cms">Simplified: AIIMS, ICMR new guidelines for treatment of patients with ‘moderate’ case of COVID-19</a>

Covishield vaccine also protects from 'double mutant' strain of COVID-19, says CCMB

<ul><li>India's expert panel has recommended SII’s Oxford-AstraZeneca COVID-19 vaccine dubbed Covishield in India for emergency use with 'restrictions.'</li><li>The SEC recommendation on Covishield has been forwarded to the Drugs Controller General of India (DCGI), which is likely to take a final call soon.</li><li>The Pune-based Serum Institute of India (SII), the world's largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield. </li></ul>An expert panel of India's drug regulator on Friday recommended emergency use approval for Oxford-AstraZeneca vaccine Covishield, being manufactured by the Serum Institute of India, paving the way for the roll-out of the first COVID-19 shot in the country in the next few days.. The SEC recommendation on Covishield has been forwarded to the Drugs Controller General of India (DCGI), which is likely to take a final call soon. The SEC, which earlier had sought additional safety, immunogenicity and efficacy data from SII and Bharat Biotech, deliberated on their applications seeking emergency use authorisation (EUA) for their shots on Wednesday, and met again on Friday to review the matter. While granting the restricted emergency use approval for the Oxford COVID-19 vaccine, the panel imposed certain regulatory provisions, including that the shot is indicated for active immunisation in individuals of 18 years or more to prevent the disease and that it should be administered intramuscularly in two doses at an interval of 4 to 6 weeks. Further, the SII should submit safety, efficacy and immunogenicity data from the ongoing clinical trials in the country and across the globe for review at the earliest. Also, the Pune-based firm should submit the safety data including the data on adverse events following immunisation (AEFI) and adverse event of special interest (AESI) with due analysis every 15 days for the first two months and monthly thereafter till the completion of the ongoing clinical trial in the country. The Pune-based Serum Institute of India (SII), the world's largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield. The approval comes at a time when the Indian government is wary of the new strain of COVID-19, which has been wreaking havoc in the UK. So far 29 cases of the new mutant variant have been detected in India. As compared to Pfizer and Moderna vaccines, the Oxford-AstraZeneca COVID-19 vaccine is <a href="https://www.businessinsider.in/india/news/india-needs-to-ramp-up-its-cold-storage-facilities-to-accommodate-the-distribution-of-the-covid-19-vaccine-within-the-country/articleshow/79422624.cms">more suited to India’s requirements</a> with storage temperature requirements of between two to eight degrees Celsius. COVID-19 vaccine candidates and the temperatures they need to survive: <table style="border-width: initial; border-style: none; width: 468pt; table-layout: fixed;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Vaccine </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cold chain </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Pfizer/BioNTech </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-70 degrees Celsius </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Moderna </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-20 degrees Celsius </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Oxford/AstraZeneca </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2-8 degrees </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Johnson and Johnson </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2-8 degrees </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Novavax </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2-8 degrees </td></tr></tbody></table>Source: Respective companies The government is also reportedly in favour of Covishield because it's considerably cheaper than Pfizer and Moderna. According to the SII, the vaccine will only cost the government $3 per dose. Pfizer, on the other hand, is selling its vaccine at $37 per dose. Cost of COVID-19 vaccines: <table style="border-width: initial; border-style: none; width: 468pt; table-layout: fixed;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">COVID-19 vaccine candidate </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Projected price per dose </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Covishield </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">$3 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Bharat Biotech </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">$3-6 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Zydus </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">$3-6 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Sputnik V </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">$10 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Pfizer </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">$37 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;"><a href="https://indianexpress.com/article/coronavirus/moderna-covid-19-vaccine-cost-7060816/">Moderna</a> </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">$25-37 </td></tr></tbody></table> SII CEO Adar Poonawalla <a href="https://www.businessinsider.in/india/news/oxford-covid-19-vaccine-india-approval-likely-to-be-considered-today/articleshow/80025755.cms">told reporters</a> on December 28 that it has 40 to 50 million vaccine doses stockpiled so far, most of which are intended for the Indian market. “We will get some good news this New Year’s… All the data has been submitted and we must respect the process as regulators evaluate data,” he said. The Indian government is also ready to roll out the vaccine having run a <a href="https://www.businessinsider.in/india/news/covid-vaccine-dry-run-prep-up-before-the-actual-vaccine-reaches-you/articleshow/79996397.cms">two-day dry run</a> of its vaccination drive. The mock exercise was aimed at end-to-end testing of Covid-19 vaccination process, including planning and preparations as per the <a href="https://www.businessinsider.in/india/news/covid-19-vaccine-punjab-completes-dry-run-for-vaccination-in-two-districts-amid-concerns-over-new-virus-strain/articleshow/80010928.cms">operational guidelines</a>. SEE ALSO: <a href="https://www.businessinsider.in/science/space/news/isro-chairman-k-sivan-gets-one-year-extension-as-space-secretary/articleshow/80038663.cms">ISRO Chairman K Sivan gets one year extension as Space Secretary</a> <a href="https://www.businessinsider.in/finance/banks/news/cbi-books-hyderabad-based-infra-firm-ivrcl-for-defrauding-eight-public-banks-for-4837-crore/articleshow/80038439.cms" data-type="tilCustomLink">CBI books Hyderabad-based infra firm IVRCL for defrauding eight public banks for ₹4,837 crore</a>

Serum’s Covishield vaccine gets expert panel recommendation, paving the way for first authorized COVID-19 shot in India

<keyword id="19910149" type="General" weightage="100" keywordseo="AstraZeneca" source="keywords" meta.keywordsubtype="org" meta.entityname="AstraZeneca" meta.hostid="261" meta.entityid="AstraZeneca">AstraZeneca</keyword> made headlines on Tuesday as it initiated the global withdrawal of its COVID-19 vaccine. This decision comes weeks after the pharmaceutical giant acknowledged the vaccine's potential to trigger a rare side effect known as <keyword id="21475609" type="General" weightage="20" keywordseo="Thrombosis-with-Thrombocytopenia-Syndrome" source="keywords">Thrombosis with Thrombocytopenia Syndrome</keyword> (TTS). Previously, AstraZeneca had admitted in court filings that its vaccine could lead to side effects like <keyword id="21303970" type="General" weightage="20" keywordseo="blood-clots" source="keywords">blood clots</keyword> and low blood platelet counts. However, the company has now attributed its <keyword id="21572759" type="General" weightage="20" keywordseo="vaccine-withdrawal" source="Orion">vaccine withdrawal</keyword> not to the aforementioned side effects, but to an "oversupply of updated vaccines" since the pandemic. The company also announced its decision to revoke the vaccine Vaxzevria's marketing authorisations within Europe, noting that the oversupply has reduced the demand for Vaxzevria, which is no longer being produced or distributed. According to The Telegraph, AstraZeneca had submitted its application to withdraw the vaccine on March 5, and the withdrawal became effective on May 7. AstraZeneca collaborated with the University of Oxford to develop the Vaxzevria vaccine, while also partnering with the <keyword id="19897707" type="General" weightage="20" keywordseo="Serum-Institute-of-India" source="keywords" meta.keywordsubtype="org" meta.entityname="Serum Institute of India" meta.hostid="261" meta.entityid="Serum Institute of India">Serum Institute of India</keyword> (SII), the world's largest vaccine manufacturer, to supply the Covishield vaccine to the Indian government. The UK-based pharma company is currently facing <keyword id="19982808" type="General" weightage="20" keywordseo="legal-action" source="keywords">legal action</keyword> alleging that its vaccine has caused deaths and severe harm to a few of those who received it. <cmsannotation type="cmsannotation" annotationid="The lawsuits against AstraZeneca" comment="subhead" text="The lawsuits against AstraZeneca">The lawsuits against AstraZeneca</cmsannotation> Families of individuals affected by adverse vaccine reactions continue to pursue legal recourse against AstraZeneca and the Serum Institute of India. <keyword id="21513237" type="General" weightage="20" keywordseo="venugopalan-govindan" source="keywords">Venugopalan Govindan</keyword>, whose daughter Karunya passed away after receiving the Covishield vaccine, expressed his grief and criticised various parties for his daughter's death. He highlighted alleged negligence in responding to early warning signs and cited missed opportunities to prevent tragedies like his daughter's passing. Eight families across India have joined forces to seek justice, emphasising their collective determination to hold accountable those they deem responsible for the tragic loss of their loved ones. Their shared resolve underscores their commitment to achieving justice and preventing similar tragedies from occurring again, he added. In the UK, <keyword id="21472612" type="General" weightage="20" keywordseo="jamie-scott" source="keywords">Jamie Scott</keyword> took legal action last year after suffering from a blood clot and brain bleed following his vaccination in April 2021. AstraZeneca initially denied a causal link between the vaccine and this particular side-effect, but later admitted in court documents that the vaccine could cause TTS in very rare cases. As many as 51 cases have reportedly been filed against AstraZeneca in the British High Court, with affected individuals and families seeking compensation totaling an estimated £100 million. (With inputs from multiple agencies)

You Searched For "Covishield vaccine" and got 5 results

After UK and US, Italy also gives green pass to Covishield vaccine

IANS

Nepal approves Covishield vaccine for emergency use

IANS

Covishield vaccine also protects from 'double mutant' strain of COVID-19, says CCMB

IANS

Serum’s Covishield vaccine gets expert panel recommendation, paving the way for first authorized COVID-19 shot in India

BI India Bureau

AstraZeneca continues to face legal action even after withdrawing its COVID vaccine! Know all about it here

Kunal Kambli

Popular Keywords

Buying Guides